Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.
Jamie BurgessMaryam FerdousiDavid GosalCheng BoonKohei MatsumotoAnne MarshallTony MakAndrew MarshallBernhard FrankRayaz A MalikUazman AlamPublished in: Oncology and therapy (2021)
The increasing prevalence of CIPN demands an objective approach to identify at-risk patients in order to prevent or limit progression and effectively alleviate the symptoms associated with CIPN. An evidence base for novel targets and both pharmacological and non-pharmacological treatments is beginning to emerge and has been recognised recently in publications by the American Society of Clinical Oncology and analgesic trial design expert groups such as ACTTION.
Keyphrases
- chemotherapy induced
- end stage renal disease
- risk factors
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- palliative care
- prognostic factors
- study protocol
- randomized controlled trial
- peritoneal dialysis
- clinical practice
- neuropathic pain
- phase ii
- phase iii
- open label
- depressive symptoms
- sleep quality